The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Published 2015 View Full Article

Authors

Keywords

afatinib, erlotinib, heregulin, non-small cell lung cancer, human epidermal growth factor receptor

Journal

Oncotarget

Volume 6, Issue 32, Pages -

Publisher

Impact Journals, LLC

Online

2015-09-30

DOI

10.18632/oncotarget.5286

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started